檢索結果 - Lahar Mehta

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

    Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial 由 David Kudrow, Roger Cady, Brent Allan, Susan Pederson, Joe Hirman, Lahar Mehta, Barbara Schaeffler

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Cost-effectiveness of disease-modifying therapy for multiple sclerosis

    Cost-effectiveness of disease-modifying therapy for multiple sclerosis 由 Katia Noyes, Alina Bajorska, A T Chappel, S. R. Schwid, Lahar Mehta, Bianca Weinstock‐Guttman, Robert G. Holloway, Andrew W. Dick

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results

    Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results 由 Lahar Mehta, Manjit McNeill, Jeremy Hobart, Kathleen W. Wyrwich, Jiat Ling Poon, Priscilla Auguste, John Zhong, Jacob Elkins

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack

    Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack 由 Paul Winner, Peter McAllister, George Chakhava, Jessica Ailani, Anders Ettrup, Mette Krog Josiassen, Annika Lindstén, Lahar Mehta, Roger Cady

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial

    Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial 由 Raymond Hupperts, Jan Lycke, Christine Short, Claudio Gasperini, Manjit McNeill, Rossella Medori, Agata Tofil-Kaluza, Maria Hovenden, Lahar Mehta, Jacob Elkins

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2

    Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2 由 Hans‐Christoph Diener, Michael J. Marmura, Stewart J. Tepper, Robert P. Cowan, Amaal J. Starling, Merle L. Diamond, Joe Hirman, Lahar Mehta, Thomas Brevig, Bjørn Sperling, Roger Cady

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials

    Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials 由 Timothy R. Smith, Egilius L.H. Spierings, Roger Cady, Joe Hirman, Barbara Schaeffler, Vivienne Shen, Bjørn Sperling, Thomas Brevig, Mette Krog Josiassen, Eric J. Brunner, Loan Honeywell, Lahar Mehta

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Five years of ocrelizumab in relapsing multiple sclerosis

    Five years of ocrelizumab in relapsing multiple sclerosis 由 Stephen L. Hauser, Ludwig Kappos, Douglas L. Arnold, Amit Bar‐Or, Bruno Brochet, Robert T. Naismith, Anthony Traboulsee, Jerry S. Wolinsky, Shibeshih Belachew, Harold Koendgen, Victoria Levesque, Marianna Manfrini, Fabian Model, Stanislas Hubeaux, Lahar Mehta, Xavier Montalbán

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: